With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...

Yes, I would like to be contacted by a representative to learn more about Bloomberg's solutions and services. By submitting this information, I agree to the privacy policy and to learn more about ...